When Trump labeled Tylenol use in pregnant women as a potential cause of autism, President Trump threw the weight of his office behind a theory that has not yet been proven and defied the guidance of his scientific advisers, Annie Linskey of The Wall Street Journal reports. “They’re waiting for certain studies,” Trump said. “I want to say it like it is: Don’t take Tylenol. Don’t take it.” Meanwhile, according to the official notice Trump’s administration released on Monday, “while an association between acetaminophen and autism has been described in many studies, a causal relationship has not been established and there are contrary studies in the scientific literature.” Tylenol is currently manufactured by Kenvue (KVUE).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Kenvue rallies 6% to $18 after Trump event on Tylenol risk
- Barclays ‘rough math’ suggests Kenvue selloff overdone
- Citi sees Kenvue rallying on Trump’s lack of scientific evidence
- Hold Rating for Kenvue, Inc. Amidst Market Reaction to Government Advisories on Acetaminophen
- Kenvue Stock (KVUE) Pops, Defying Trump’s Claim Linking Tylenol to Autism